Pfizer Inc. (PFE)
Pfizer moves forward with once-daily weight-loss pill to compete with Wegovy
Pfizer plans to move a reworked, once-a-day version of its weight-loss pill danuglipron into clinical trials later this year, the company said on Thursday.
Pfizer Stock Rises as Company Advances Studies of Once-a-Day Weight-Loss Pill
Shares of Pfizer (PFE) advanced as the drug maker announced that it was moving forward with research into a potential once-a-day weight-loss pill.
Pfizer advances once-daily weight-loss pill in ongoing study
Pfizer announced that it's advancing its oral weight-loss treatment, called danuglipron, to the next round in an ongoing study after seeing "encouraging" results.
Pfizer Vs. Eli Lilly Stock – Which Is A Better Pick?
We believe that Eli Lilly stock (NYSE: LLY) is currently a better pick than its industry peer – Pfizer stock , given its better prospects. PFE stock trades at a much lower multiple of 2.8x revenues, versus 23.5x for LLY, and we think this gap in valuation will remain wide in favor of Eli Lilly.
Pfizer Moves Forward With Weight-Loss Pill. The Stock Is Rising.
Pfizer is advancing the development of its once-daily weight loss pill, danuglipron.
Pfizer says it has identified and selected a preferred formulation for its one-a-day obesity pill
Pfizer Inc.'s stock PFE rose 2.4% early Thursday, after the drug company said it has identified and selected a formulation for its once-daily pill to treat obesity. “Obesity is a key therapeutic area for Pfizer, and the company has a robust pipeline of three clinical and several pre-clinical candidates,” Dr. Mikael Dolsten, chief scientific officer and president of R&D said in a statement. “The most advanced of them, danuglipron, has demonstrated good efficacy in a twice-daily formulation, and we believe a once-daily formulation has the potential to have a competitive profile in the oral GLP-1 space.” The company is...
CureVac Provides Update on Trial Dates for Patent Litigation Across Multiple Geographies Against Pfizer/BioNTech
New trial date for U.S. patent litigation set for March 3, 2025, following settlement with Acuitas Therapeutics First instance decision on validity of EP 3 708 668 B1 (split poly-A tail technology) scheduled for March 25, 2025, by European Patent Office in the context of the German patent litigation UK trial on validity of intellectual property rights EP 3 708 668 B1 and EP 4 023 755 B1 (split poly-A tail technology) began July 10; judgement expected later in 2024 TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / July 11, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the latest trial dates for its ongoing patent litigation against Pfizer/BioNTech in multiple geographies including the U.S., UK and Germany.
Pfizer moves forward with once-daily version of weight loss pill after setbacks
Pfizer said it will continue to develop the once-daily version of its weight loss pill, danuglipron, after it saw "encouraging" data in an early-stage trial. The company plans to conduct studies in the second half of the year evaluating multiple doses of the drug.
Pfizer moves forward with once-daily weight loss pill
Pfizer said on Thursday it would advance a reworked, once-a-day version of its experimental obesity pill, danuglipron to clinical trials in the second half of this year, sending its shares 5% higher in premarket trading.
Evotec and Pfizer Collaborate to Advance Drug Discovery in France
Multi-year collaboration will initially focus on early discovery research for metabolic and infectious diseases HAMBURG, GERMANY / ACCESSWIRE / July 10, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)(NASDAQ:EVO) (MDAX/TecDAX , ISIN: DE0005664809) today announced it has entered into a multi-year master research collaboration and option and license agreement with Pfizer. Under the agreement, Evotec and Pfizer will initially focus on early discovery research for metabolic and infectious diseases.
Pfizer: Buy This Big Yielder On The Strong Pipeline
Pfizer's cash flow from operations in 2022 was $29.267 billion, driven by COVID-19 vaccine and Paxlovid sales, but dropped to $8.7 billion in 2023. Despite revenue loss from COVID-19 drugs, the Company has a strong drug pipeline and scale advantage over rivals. Facing patent expirations and challenges from the US Inflation Reduction Act, PFE focuses on oncology drugs, biologics, and future revenue growth.
Pfizer's longtime science chief Mikael Dolsten to step down
Pfizer said on Tuesday its chief scientific officer Mikael Dolsten, a key figure behind the development of the company's COVID-19 vaccine, would step down after a more than 15-year career at the drugmaker.
